249 related articles for article (PubMed ID: 31853058)
21. BRCA1/2 missense mutations and the value of in-silico analyses.
Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
[TBL] [Abstract][Full Text] [Related]
22. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
[TBL] [Abstract][Full Text] [Related]
23. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
[TBL] [Abstract][Full Text] [Related]
24. Reclassification of
Ha HI; Ryu JS; Shim H; Kong SY; Lim MC
J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592
[TBL] [Abstract][Full Text] [Related]
25. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
[TBL] [Abstract][Full Text] [Related]
26. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.
Easton DF; Deffenbaugh AM; Pruss D; Frye C; Wenstrup RJ; Allen-Brady K; Tavtigian SV; Monteiro AN; Iversen ES; Couch FJ; Goldgar DE
Am J Hum Genet; 2007 Nov; 81(5):873-83. PubMed ID: 17924331
[TBL] [Abstract][Full Text] [Related]
27. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
28. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
[TBL] [Abstract][Full Text] [Related]
29.
Lourenço RA; Lança M; Monteiro Gil O; Cardoso J; Lourenço T; Pereira-Leal JB; Rodrigues AS; Rueff J; Nunes Silva S
Mol Med Rep; 2023 Jul; 28(1):. PubMed ID: 37232349
[TBL] [Abstract][Full Text] [Related]
30. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
31. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS).
Lindor NM; Guidugli L; Wang X; Vallée MP; Monteiro AN; Tavtigian S; Goldgar DE; Couch FJ
Hum Mutat; 2012 Jan; 33(1):8-21. PubMed ID: 21990134
[TBL] [Abstract][Full Text] [Related]
32. Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay.
Hu C; Susswein LR; Roberts ME; Yang H; Marshall ML; Hiraki S; Berkofsky-Fessler W; Gupta S; Shen W; Dunn CA; Huang H; Na J; Domchek SM; Yadav S; Monteiro ANA; Polley EC; Hart SN; Hruska KS; Couch FJ
Clin Cancer Res; 2022 Sep; 28(17):3742-3751. PubMed ID: 35736817
[TBL] [Abstract][Full Text] [Related]
33. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
[TBL] [Abstract][Full Text] [Related]
35. Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
Billaud A; Chevalier LM; Augereau P; Frenel JS; Passot C; Campone M; Morel A
Genome Med; 2021 Nov; 13(1):174. PubMed ID: 34749799
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
37. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
38. Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
Caputo SM; Golmard L; Léone M; Damiola F; Guillaud-Bataille M; Revillion F; Rouleau E; Derive N; Buisson A; Basset N; Schwartz M; Vilquin P; Garrec C; Privat M; Gay-Bellile M; Abadie C; Abidallah K; Airaud F; Allary AS; Barouk-Simonet E; Belotti M; Benigni C; Benusiglio PR; Berthemin C; Berthet P; Bertrand O; Bézieau S; Bidart M; Bignon YJ; Birot AM; Blanluet M; Bloucard A; Bombled J; Bonadona V; Bonnet F; Bonnet-Dupeyron MN; Boulaire M; Boulouard F; Bouras A; Bourdon V; Brahimi A; Brayotel F; Bressac de Paillerets B; Bronnec N; Bubien V; Buecher B; Cabaret O; Carriere J; Chiesa J; Chieze-Valéro S; Cohen C; Cohen-Haguenauer O; Colas C; Collonge-Rame MA; Conoy AL; Coulet F; Coupier I; Crivelli L; Cusin V; De Pauw A; Dehainault C; Delhomelle H; Delnatte C; Demontety S; Denizeau P; Devulder P; Dreyfus H; d'Enghein CD; Dupré A; Durlach A; Dussart S; Fajac A; Fekairi S; Fert-Ferrer S; Fiévet A; Fouillet R; Mouret-Fourme E; Gauthier-Villars M; Gesta P; Giraud S; Gladieff L; Goldbarg V; Goussot V; Guibert V; Guillerm E; Guy C; Hardouin A; Heude C; Houdayer C; Ingster O; Jacquot-Sawka C; Jones N; Krieger S; Lacoste S; Lallaoui H; Larbre H; Laugé A; Le Guyadec G; Le Mentec M; Lecerf C; Le Gall J; Legendre B; Legrand C; Legros A; Lejeune S; Lidereau R; Lignon N; Limacher JM; Doriane Livon ; Lizard S; Longy M; Lortholary A; Macquere P; Mailliez A; Malsa S; Margot H; Mari V; Maugard C; Meira C; Menjard J; Molière D; Moncoutier V; Moretta-Serra J; Muller E; Nevière Z; Nguyen Minh Tuan TV; Noguchi T; Noguès C; Oca F; Popovici C; Prieur F; Raad S; Rey JM; Ricou A; Salle L; Saule C; Sevenet N; Simaga F; Sobol H; Suybeng V; Tennevet I; Tenreiro H; Tinat J; Toulas C; Turbiez I; Uhrhammer N; Vande Perre P; Vaur D; Venat L; Viellard N; Villy MC; Warcoin M; Yvard A; Zattara H; Caron O; Lasset C; Remenieras A; Boutry-Kryza N; Castéra L; Stoppa-Lyonnet D
Am J Hum Genet; 2021 Oct; 108(10):1907-1923. PubMed ID: 34597585
[TBL] [Abstract][Full Text] [Related]
39.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
